About Biocon Biologics Limited
Data last updated: 23 December 2025
Biocon Biologics Limited is a public limited company based in Bengaluru, Karnataka, India, a subsidiary of Biocon Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 08 June 2016, the company has been in operation for over 10 years.
Registered with ROC Bangalore under CIN U24119KA2016PLC093936.
Capital: an authorised share capital of ₹3,500 Cr and a paid-up capital of ₹1,819.87 Cr. Formerly known as Biocon Biologics India Limited. It is led by directors including Bobby Kanubhai Parikh and Kiran Mazumdar Shaw.
Last AGM: 25 July 2025. Financial statements filed for year ended 31 March 2025. Office: Biocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – Ii Hosur Road, Bengaluru, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹10,144 Cr, a growth of 13% compared to the previous year.
The company has a workforce of approximately 5,280 employees as per the latest available data. It operates as a subsidiary of Biocon Limited.
As per MCA filings, the company has open charges of ₹9,543.66 Cr and satisfied charges of ₹18,987 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressBiocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – Ii Hosur Road, Bengaluru, Karnataka, India – 560100
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Biocon Biologics Limited
Biocon Biologics Limited has one previous CIN (Corporate Identification Number): U24119KA2016FLC093936. The current CIN is U24119KA2016PLC093936, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24119KA2016PLC093936 | Current |
| U24119KA2016FLC093936 | Previous |
Business Activity of Biocon Biologics Limited
Biocon Biologics Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Biocon Biologics Limited
Biocon Biologics Limited is audited by B S R & Co. LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B S R & Co. LLP | blur-value | blur-value | blur-value |
Board of Directors of Biocon Biologics Limited
Biocon Biologics Limited is currently managed by 11 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bobby Kanubhai Parikh | Director | 01 Aug 2019 | 6 Years 11 Months | Current |
| Kiran Mazumdar Shaw | Whole-Time Director | 08 Jun 2016 | 10 Years 1 Months | Current |
|
Daniel Mark Bradbury
Also directs:
Biocon Biologics Limited
|
Director | 01 Aug 2019 | 6 Years 11 Months | Current |
|
Rajiv Malik
Also directs:
Biocon Biologics Limited, Gurujee Consulting Llp, Mylan Laboratories Limited and 1 more
|
Nominee Director | 29 Nov 2022 | 3 Years 7 Months | Current |
|
Peter Baron Piot
Also directs:
Biocon Biologics Limited, Biological E. Limited
|
Director | 21 Jan 2021 | 5 Years 5 Months | Current |
|
Shreehas Pradeep Tambe
Also directs:
Biocon Biologics Limited
|
Ceo | 05 Dec 2022 | 3 Years 7 Months | Current |
Financials of Biocon Biologics Limited FY 2025 filings available
Biocon Biologics Limited reported revenue of ₹10,144 Cr (up 13% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Biocon Biologics Limited
As of FY 2023, Biocon Biologics Limited's shareholding pattern shows 92.04% by promoters, 1.50% by domestic institutional investors (DII), 5.27% by public shareholders, 1.19% by others. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Biocon Biologics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Dec 2024 | Others | ₹2,734.9 Cr | Open |
| 22 Nov 2024 | Others | ₹6,808.76 Cr | Open |
| 06 Mar 2023 | The Hongkong and Shanghai Banking Corporation Limited | ₹9,841.76 Cr | Satisfied |
| 03 Mar 2023 | Others | ₹7,947.94 Cr | Satisfied |
| 13 Sep 2021 | Others | ₹200 Cr | Satisfied |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Biocon Biologics Limited
Biocon Biologics Limited has a workforce of 5,280 employees as of Apr 02, 2024.
Employee Count & EPFO Data of Biocon Biologics Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Biocon Biologics Limited
GSTIN & GST Filing Data of Biocon Biologics Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Biocon Biologics Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Biocon Biologics Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Biocon Biologics Limited
MSME Payment Delays by Biocon Biologics Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Biocon Biologics Limited
Subsidiaries & Group Companies of Biocon Biologics Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Biocon Biologics Limited with ownership details.
MCA Filings & Documents of Biocon Biologics Limited
MCA Filings & Documents of Biocon Biologics Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Biocon Biologics Limited
Recent News on Biocon Biologics Limited
Frequently Asked Questions about Biocon Biologics Limited
Biocon Biologics Limited is an active public limited company in the pharma sector based in Bengaluru, Karnataka, India. It was incorporated on 08 June 2016 (10+ years old) and is registered under CIN U24119KA2016PLC093936. The company has 5,280 employees.
Biocon Biologics Limited reported revenue of ₹10,144 Cr for FY 2025 (up 13.00% YoY).
The current directors of Biocon Biologics Limited are:
The primary industry of Biocon Biologics Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Biocon Biologics Limited can be reached at the registered office: Biocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – Ii Hosur Road, Bengaluru, Karnataka, India – 560100, or through the website biocon.com.
The authorised capital is ₹3,500 Cr, and the paid-up capital is ₹1,819.87 Cr.